Pasithea Therapeutics (KTTA) Capital Expenditures (2021 - 2023)
Pasithea Therapeutics (KTTA) posted Capital Expenditures of -$36.0 for Q4 2023, up 99.84% sequentially from -$22659.0 in Q3 2023, and down 100.04% YoY from $92725.0 in Q4 2022.
Pasithea Therapeutics (KTTA) Capital Expenditures (2021 - 2023) Analysis & Trends
Pasithea Therapeutics has reported Capital Expenditures for 3 years, with the latest figure at -$36.0 in Q4 2023.
- Quarterly Capital Expenditures fell 100.04% year-over-year to -$36.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $34301.0 (down 67.97% YoY) and the FY2023 annual result came in at $34301.0, down 67.97% from the prior year.
- Capital Expenditures rose to -$36.0 in Q4 2023 per KTTA's latest filing, from -$22659.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $92725.0 in Q4 2022 and troughed at -$22659.0 in Q3 2023.
- A 3-year average of $17148.3 and a median of $5486.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 2662.07% in 2023, down 513.03% in 2023.
- Over 3 years, Capital Expenditures stood at $12933.0 in 2021, then jumped by 616.96% to $92725.0 in 2022, then tumbled by 100.04% to -$36.0 in 2023.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$36.0, -$22659.0, and $3108.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -36.00 |
| Dec 31, 2023 | -36.00 |
| Sep 30, 2023 | -22,659.00 |
| Sep 30, 2023 | -22,659.00 |
| Jun 30, 2023 | 3,108.00 |
| Jun 30, 2023 | 3,108.00 |
| Mar 31, 2023 | 53,888.00 |
| Mar 31, 2023 | 53,888.00 |
| Dec 31, 2022 | 92,725.00 |
| Dec 31, 2022 | 92,725.00 |
| Sep 30, 2022 | 5,486.00 |
| Sep 30, 2022 | 5,486.00 |
| Jun 30, 2022 | 6,939.00 |
| Jun 30, 2022 | 6,939.00 |
| Mar 31, 2022 | 1,951.00 |
| Mar 31, 2022 | 1,951.00 |
| Dec 31, 2021 | 12,933.00 |
| Dec 31, 2021 | 12,933.00 |